联系客服

002349 深市 精华制药


首页 公告 精华制药:2023年年度报告摘要

精华制药:2023年年度报告摘要

公告日期:2024-04-19

精华制药:2023年年度报告摘要 PDF查看PDF原文

          证券代码:002349                证券简称:精华制药                公告编号:2024-007

    精华制药集团股份有限公司 2023 年年度报告摘要

一、重要提示
本年度报告摘要来自年度报告全文,为全面了解本公司的经营成果、财务状况及未来发展规划,投资者应当到证监会指
定媒体仔细阅读年度报告全文。
所有董事均已出席了审议本报告的董事会会议。
非标准审计意见提示
□适用 不适用
董事会审议的报告期利润分配预案或公积金转增股本预案
适用 □不适用
是否以公积金转增股本
□是 否

公司经本次董事会审议通过的利润分配预案为:以 814,180,908 为基数,向全体股东每 10 股派发现金红利 0.92 元(含

税),送红股 0 股(含税),不以公积金转增股本。
董事会决议通过的本报告期优先股利润分配预案
□适用 □不适用
二、公司基本情况
1、公司简介

 股票简称                                                精华制药        股票代码        002349

 股票上市交易所                                          深圳证券交易所

                    联系人和联系方式                            董事会秘书            证券事务代表

 姓名                                                    王剑锋                  樊屹秋

                                                          南通市崇川区青年中路    南通市崇川区青年中路

 办公地址                                                198 号国城生活广场办公  198 号国城生活广场办公
                                                          楼 A 幢 23 层            楼 A 幢 25 层

 传真                                                    0513-85609115          0513-85609115

 电话                                                    0513-85609123          0513-85609158

 电子信箱                                                it@jhoa.net            fyq@jhoa.net

2、报告期主要业务或产品简介

主要类别    主要产品                                产品功能或用途


中成药制剂  王氏保赤丸                              用于小儿乳滞疳积、痰厥惊
                                                    风、喘咳痰鸣、乳食减少、
                                                    吐泻发热、大便秘结、四时
                                                    感冒以及脾胃虚弱、发育不
                                                    良等症。成人肠胃不清、痰
                                                    食阻滞者亦有疗效。

            季德胜                                  具有清热解毒、消肿镇痛功
                                                    效,除主治毒蛇、毒虫咬伤
            蛇药片                                  外,还具有消炎、抗菌、祛
                                                    肿、化腐生肌、改善微循

                                                    环、调节机体免疫力等作

                                                    用,对病毒感染、细菌感

                                                    染、免疫缺陷等疾病疗效独
                                                    特。

            正柴胡饮颗粒                            用于外感风寒初起,发热恶
                                                    寒、无汗、头痛、鼻塞、喷
                                                    嚏、咽痒咳嗽、四肢酸痛等
                                                    症,适用于流行性感冒初

                                                    起、轻度上呼吸道感染等疾
                                                    患

中药材及中药当归、白芍等                            当归具有补血活血等功效,
饮片                                                不同中药材及饮片具有不同
                                                    的功效。

化学原料药及苯巴比妥                                具有镇静、安眠、抗惊厥和
中间体                                              抗癫痫作用

            氟尿嘧啶                                抗肿瘤作用

化工医药中间二氧六环                                含氧杂环类化工医药中间体

体          甲基肼                                  用来生产头孢曲松钠、氟喹
                                                    诺酮类抗菌药、替莫唑胺等
                                                    原料药及农药所需的化工医
                                                    药中间体

3、主要会计数据和财务指标
(1) 近三年主要会计数据和财务指标
公司是否需追溯调整或重述以前年度会计数据
是 □否
追溯调整或重述原因
会计政策变更

                                                                                                      元

              2023 年末                    2022 年末                本年末比上年              2021 年末

                                                                      末增减


                                      调整前            调整后          调整后          调整前          调整后

总资产          3,185,011,365.95  3,041,677,568.76  3,041,919,045.42          4.70%  3,198,096,241.82  3,199,184,48
                                                                                                                    2.12

归属于上市公                                                                                                2,235,809,71
司股东的净资    2,444,593,197.18  2,400,966,083.66  2,400,929,734.88          1.82%  2,235,838,542.50          3.59


                                                2022 年                本年比上年增              2021 年

                    2023 年                                                  减

                                      调整前            调整后          调整后          调整前          调整后

营业收入        1,511,751,346.97  1,573,059,814.20  1,573,059,814.20        -3.90%  1,357,868,013.63  1,357,868,01
                                                                                                                    3.63

归属于上市公                                                                                                160,673,331.
司股东的净利      247,697,195.98    212,232,945.44    212,225,425.57        16.71%    160,702,159.91            00

归属
[点击查看PDF原文]